Dr. Reddy's Laboratories Limited (RDY)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 2
Do Nothing: qualitativeScore is 2 (below required floor of 3); strategy blocks new longs and the chart remains only an oversold bounce attempt inside a strong downtrend.
Company overview
Dr. Reddy's Laboratories Limited is a global pharmaceutical company based in Hyderabad, India. It operates through segments such as Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The company focuses on manufacturing generic pharmaceuticals, active pharmaceutical ingredients, and developing proprietary formulations, with a strong emphasis on oncology and inflammatory treatments.
Fundamental
fairStrong balance sheet and growth, but margin compression and regulatory risks create uncertainty.
FundamentalScore 3/5: strong balance sheet and multi-year growth, but FY2026 margin compression and a recent FDA Form 483 disclosure add uncertainty while valuation remains only moderately attractive. Discounted-cash-flow outputs are mixed (levered value roughly in-line with the market; unlevered implies ~30% upside), so there isn’t a clear margin-of-safety setup right now.
Sentiment
weakRecent FDA observations and earnings concerns weigh on sentiment, with no clear bullish catalysts.
Near-term coverage skews slightly negative after Q1 FY27 earnings commentary (announced) and a fresh USFDA Form 483 disclosed via issuer 6-K (regulator_confirmed); sentiment delta vs the 30–90d baseline is indeterminate because the baseline sentiment run timed out. Legal tools show no regulator-confirmed fraud/accounting probe—only plaintiff-law-firm solicitation “investigation” PRs.
Technical
weakThe stock remains in a strong downtrend, with only oversold bounce potential.
Downtrend still dominates: price sits below the SMA20/50/200, EMA9/21, and the latest daily VWAP, while MACD remains below both signal and zero. RSI 31.91 and Williams %R -82.91 are oversold, but ADX 36.99 confirms trend strength, so this is only a bounce candidate, not a confirmed bullish reversal.
You’re looking at 2026-07-30 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.